Scrip Asia 100: Sales blown off course by currency headwinds
This article was originally published in Scrip
Executive Summary
Fiscal 2013 was a difficult year for Asian drug producers. 2013 drug revenues were $128bn, 5.1% down on 2012 levels ($136bn) across the 85 publicly-traded pharmaceutical companies that constitute the Scrip Asia 100 (see Table 1 for detail).